The substantial beat on both earnings per share and sales forecasts for HOOKIPA Pharma indicates a strong operational performance and significant growth, likely leading to increased investor confidence and a positive short-term impact on the stock price. The company's performance far exceeded analysts' expectations, which could lead to upward revisions in stock price targets and ratings by analysts, further fueling positive momentum in the stock.